AngioDynamics (ANGO) Projected to Post Earnings on Wednesday

AngioDynamics (NASDAQ:ANGO) is anticipated to release its earnings data before the market opens on Wednesday, April 2nd. Analysts expect AngioDynamics to post earnings of ($0.13) per share and revenue of $70.30 million for the quarter. AngioDynamics has set its FY 2025 guidance at -0.380–0.340 EPS and its FY25 guidance at ($0.38)-($0.34) EPS.Parties that wish to listen to the company’s conference call can do so using this link.

AngioDynamics (NASDAQ:ANGO) last released its quarterly earnings results on Wednesday, January 8th. The medical instruments supplier reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.07. AngioDynamics had a negative return on equity of 7.26% and a negative net margin of 79.38%. The business had revenue of $72.90 million during the quarter, compared to analysts’ expectations of $70.93 million. During the same quarter last year, the business posted ($0.05) EPS. The firm’s revenue for the quarter was down .1% compared to the same quarter last year. On average, analysts expect AngioDynamics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

AngioDynamics Price Performance

NASDAQ:ANGO opened at $10.18 on Wednesday. The company has a market cap of $411.94 million, a price-to-earnings ratio of -1.81 and a beta of 0.56. AngioDynamics has a 1 year low of $5.30 and a 1 year high of $13.50. The stock’s 50 day simple moving average is $10.57 and its two-hundred day simple moving average is $8.76.

Insider Activity at AngioDynamics

In other AngioDynamics news, SVP Warren Nighan, Jr. sold 4,060 shares of AngioDynamics stock in a transaction on Thursday, January 16th. The shares were sold at an average price of $12.31, for a total transaction of $49,978.60. Following the completion of the transaction, the senior vice president now directly owns 41,817 shares of the company’s stock, valued at $514,767.27. The trade was a 8.85 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 5.40% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Separately, HC Wainwright lifted their price objective on shares of AngioDynamics from $14.00 to $15.00 and gave the stock a “buy” rating in a research note on Friday, January 10th.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.